Safety, Efficacy and Pharmacokinetics of Anidulafungin in Patients 1 Month to <2 Years of Age With Invasive Candidiasis, Including Candidemia

Pediatr Infect Dis J. 2020 Apr;39(4):305-309. doi: 10.1097/INF.0000000000002568.

Abstract

Nineteen patients 1 month to <2 years of age with (n = 16) or at high risk of (n = 3) invasive candidiasis received anidulafungin for 5-35 days (3 mg/kg day 1, 1.5 mg/kg daily thereafter) followed by optional fluconazole (NCT00761267). Most treatment-emergent adverse events were mild/moderate, and no treatment-related deaths occurred. End of intravenous therapy global response success rate was 68.8%. Pharmacokinetics were similar to adult patients.

Publication types

  • Clinical Trial, Phase III
  • Multicenter Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Administration, Intravenous
  • Anidulafungin / pharmacokinetics*
  • Anidulafungin / therapeutic use*
  • Antifungal Agents / pharmacokinetics*
  • Antifungal Agents / therapeutic use*
  • Candidemia / drug therapy*
  • Candidiasis, Invasive / drug therapy*
  • Female
  • Humans
  • Infant
  • Infant, Newborn
  • Male
  • Prospective Studies
  • Treatment Outcome

Substances

  • Antifungal Agents
  • Anidulafungin

Associated data

  • ClinicalTrials.gov/NCT00761267